紫杉醇联合NDP方案和联合DDP方案治疗非小细胞肺癌的临床疗效观察  

Nedaplain and cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：孙超[1] 时会云[1] 袁东朋[1] 

机构地区：[1]东海县人民医院胸外科,江苏东海222300

出　　处：《海南医学》2010年第11期28-30,共3页Hainan Medical Journal

摘　　要：目的对比分析紫杉醇联合奈达铂化疗方案和联合顺铂化疗方案分别治疗晚期非小细胞肺癌的疗效及毒性反应。方法 150例晚期NSCLC患者随机分为奈达铂(NDP)组76例和顺铂(DDP)组74例,两组病人的临床基本特征无显著差异,每例均保证至少进行两个周期的化疗。化疗两个周期后2-3周评价临床疗效。结果 NDP组的治疗有效率为50.0%,与DDP组(48.65%)比较差异无统计学意义(P>0.05)。主要的毒副反应为骨髓抑制和消化道反应,两组骨髓抑制发生率差异无统计学意义(P>0.05),但NDP组消化道反应明显轻于DDP组(P<0.05)。绝大多数患者耐受性良好。结论紫杉醇联合NDP方案治疗晚期NSCLC与联合DDP方案临床疗效相当,但不良反应较轻,显著提高病人的生活质量,值得进一步推广应用。Objective To evaluate the efficacy and toxic reaction of combined chemotherapy with nedaplatin and cisplatin for advanced non-small cell lung cancer（NSCLC）.Methods A total of 150 patients with advanced non-small cell lung cancer were divided into the nedaplatin group（group NDP,n=76）and the cisplatin（group DDP,n=74）.There was no significant difference of clinical characteristics between two groups.Each case was guaranteed for at least two cycles of chemotherapy.The clinical efficacy was evaluated after 2-3 weeks.Results The efficacy of group NDP was 50.0% and group DDP was 48.65%.There was no significant difference between two groups（P〉0.05）.The main toxic and side reaction were bone marrow depression and digestive reaction.There was no significant difference in the incidence of bone marrow depression between two groups.A lower response rate of digestive reaction occurred in group NDP compared to that occurred in group DDP,with a significant difference between the two groups（P〈0.05）.Most cases showed better tolerance.Conclusion The effect of combined chemotherapy with nedaplatin is similar as combined with cisplatin for advanced NSCLC,with milder adverse reactions.

关 键 词：奈达铂 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]